Oluwatobi Babajide Ayelaagbe

Oluwatobi Babajide Ayelaagbe

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2025 in Next Bioengineering
Verified
Journal Article
Open access
DIDon Eliseo Lucero-Prisno III
Don Eliseo Lucero-Prisno III
Okesanya John OlalekanOkesanya John Olalekan
Okesanya John Olalekan
AAAbdulmajeed Opeyemi Agboola
Abdulmajeed Opeyemi Agboola
Uthman Okikiola AdebayoUthman Okikiola Adebayo
Uthman Okikiola Adebayo
Olaniyi Abideen AdigunOlaniyi Abideen Adigun
Olaniyi Abideen Adigun
DODavid Bamidele Olawade
David Bamidele Olawade

31 October 2025 in Next Nanotechnology
Verified
Journal Article
Open access
TOTolutope Adebimpe Oso
Tolutope Adebimpe Oso
Uthman Okikiola AdebayoUthman Okikiola Adebayo
Uthman Okikiola Adebayo
OOOlalekan John Okesanya
Olalekan John Okesanya
CCClement Ngele Chukwu
Clement Ngele Chukwu
OAOluwatobi Babajide Ayelaagbe
Oluwatobi Babajide Ayelaagbe
DIDon Eliseo Lucero-Prisno Iii
Don Eliseo Lucero-Prisno Iii

12 November 2025 in Beni-Suef University Journal of Basic and Applied Sciences
Verified
Journal Article
Open access
PDF file
TOTolutope Adebimpe Oso
Tolutope Adebimpe Oso
Okesanya John OlalekanOkesanya John Olalekan
Okesanya John Olalekan
Uthman Okikiola AdebayoUthman Okikiola Adebayo
Uthman Okikiola Adebayo
OAOluwatobi Babajide Ayelaagbe
Oluwatobi Babajide Ayelaagbe
KOKhalifat Boluwatife Obadeyi
Khalifat Boluwatife Obadeyi
DIDon Eliseo Lucero-Prisno Iii
Don Eliseo Lucero-Prisno Iii
Antimicrobial resistance (AMR) is a crucial global health threat that reduces the effectiveness of conventional antibiotics and contributes to significant morbidity, mortality, and economic burdens, particularly in low-resource settings. This review harnesses the transformative potential of nanotechnology to mitigate the complex issues of AMR from a multidisciplinary perspective. Metal-based nanoparticles, such as silver, zinc oxide, and copper oxide, exhibit strong bactericidal activity through mechanisms including membrane disruption, reactive oxygen species generation, and the release of toxic metal ions. Carbon-based nanomaterials, such as graphene oxide, carbon nanotubes, and carbon dots, further enhance antimicrobial efficacy owing to their high surface area and customizable functionalization. Smart nanocarriers, including liposomes, dendrimers, and polymeric nanoparticles, enable targeted drug delivery, co-delivery of synergistic agents, and controlled stimuli-responsive release, thereby improving therapeutic efficacy while limiting systemic toxicity. In addition, nanosensors with colorimetric, electrochemical, fluorescent, and surface-enhanced Raman spectroscopy properties demonstrate significant promise for the rapid and sensitive diagnosis of resistant pathogens, including applications in point-of-care testing. Clinical and preclinical studies have demonstrated the effectiveness of nanoparticle-based treatments against multidrug-resistant infections, including methicillin-resistant Staphylococcus aureus, drug-resistant tuberculosis, Escherichia coli, and Pseudomonas aeruginosa. However, challenges such as toxicity concerns, manufacturing scalability, regulatory uncertainties, and environmental risks are significant issues. Despite these advances, their translation into clinical practice remains limited. Current evidence is largely derived from in vitro and animal studies, with relatively few human trials, and long-term safety data are lacking in this regard. Concerns persist regarding their toxicity, biodistribution, cost, regulatory frameworks, and potential environmental impacts. Furthermore, emerging evidence suggests that bacteria may also develop adaptive responses to nanoparticles. Collectively, these findings underscore the potential of nanotechnology in AMR management while emphasizing the critical need for systematic safety studies, clinical validation, and regulatory standardization. Nanotechnology holds significant potential for combating AMR; however, its clinical success and translation depend on bridging the gap between laboratory innovation and safe, equitable, and sustainable clinical application.

7 May 2026 in Discover Public Health
Verified
Journal Article
Open access
Okesanya John OlalekanOkesanya John Olalekan
Okesanya John Olalekan
Uthman Okikiola AdebayoUthman Okikiola Adebayo
Uthman Okikiola Adebayo
TOTolutope Adebimpe Oso
Tolutope Adebimpe Oso
OAOluwatobi Babajide Ayelaagbe
Oluwatobi Babajide Ayelaagbe
KOKhalifat Boluwatife Obadeyi
Khalifat Boluwatife Obadeyi
DIDon Eliseo Lucero-Prisno III
Don Eliseo Lucero-Prisno III

25 March 2026 in Journal of Alzheimer's Disease Reports
Verified
Journal Article
Open access
TOTolutope Adebimpe Oso
Tolutope Adebimpe Oso
Okesanya John OlalekanOkesanya John Olalekan
Okesanya John Olalekan
Uthman Okikiola AdebayoUthman Okikiola Adebayo
Uthman Okikiola Adebayo
KOKhalifat Boluwatife Obadeyi
Khalifat Boluwatife Obadeyi
OAOluwatobi Babajide Ayelaagbe
Oluwatobi Babajide Ayelaagbe
DIDon Eliseo Lucero-Prisno III
Don Eliseo Lucero-Prisno III
Background: Growing evidence implicates the gut–brain axis in Alzheimer's disease (AD), with gut microbiome dysbiosis proposed to modulate neuroinflammation, amyloid pathology, and cognitive decline. Objective: To systematically synthesize human studies (2021–2025) profiling gut microbiomes in AD; identify consistent taxonomic and functional signatures; map geographic study distribution; and highlight translational gaps. Methods: A PRISMA-compliant systematic review of human studies using 16S rRNA, metagenomics, metatranscriptomics, or fecal microbiota transplantation (FMT)/probiotic designs was conducted. Two reviewers screened studies and assessed quality using Joanna Briggs Institute tools. Owing to heterogeneity, findings were narratively synthesized across microbiome diversity, taxonomy, function, metabolism, oral–brain links, causality, interventions, and predictive analyses. Results: Thirty-seven studies, mainly from Asia with some from Europe, North America, and Africa, revealed consistent gut dysbiosis in AD. Findings show reduced alpha-diversity, loss of short-chain fatty acid-producing bacteria (e.g., Faecalibacterium prausnitzii , Bifidobacterium ), and enrichment of pro-inflammatory taxa ( Escherichia/Shigella , Proteobacteria ). Functional analyses indicate reduced butyrate synthesis, disrupted lipid and tryptophan–kynurenine metabolism, and links with apolipoprotein epsilon (ε4) gene and cognition. Limited causal evidence arises from Mendelian randomization and small FMT trials, with randomized, longitudinal confirmation still needed. Conclusions: Current evidence suggests a biologically plausible association between gut microbiota and AD pathogenesis, positioning microbiome-derived biomarkers and interventions as promising but still exploratory avenues. Harmonized, longitudinal, multi-omic, and geographically inclusive studies are urgently needed to clarify causal mechanisms and translate these correlational findings into validated diagnostics and therapeutics.

12 March 2026 in Sage Open Pediatrics
Verified
Journal Article
Open access
SJSafayet Jamil
Safayet Jamil
Uthman Okikiola AdebayoUthman Okikiola Adebayo
Uthman Okikiola Adebayo
KOKhalifat Boluwatife Obadeyi
Khalifat Boluwatife Obadeyi
Okesanya John OlalekanOkesanya John Olalekan
Okesanya John Olalekan
OAOluwatobi Babajide Ayelaagbe
Oluwatobi Babajide Ayelaagbe
TOTolutope Adebimpe Oso
Tolutope Adebimpe Oso